

PROSTAGLANDIN E₂ AS A MEDIATOR OF FEVER: SYNTHESIS AND CATABOLISM

Andrei I. Ivanov¹ and Andrej A. Romanovsky²

¹ Department of Pathology and Laboratory Medicine, Emory University, Atlanta, GA 30322, USA, ² Systemic Inflammation Laboratory, Trauma Research, St. Joseph's Hospital and Medical Center, Phoenix, AZ 85013, USA

TABLE OF CONTENTS

1. Abstract
2. Introduction
3. Synthesis of prostaglandin E₂ in fever
 - 3.1. Three steps of the enzymatic cascade
 - 3.2. Step 1: phospholipases A₂
 - 3.2.1. Calcium-dependent cytosolic phospholipases A₂
 - 3.2.2. Secretory phospholipases A₂
 - 3.3. Step 2: cyclooxygenases
 - 3.3.1. Cyclooxygenase-1
 - 3.3.2. Cyclooxygenase-2
 - 3.4. Step 3: terminal synthases
 - 3.4.1. Microsomal prostaglandin E synthase-1
 - 3.4.2. Cytosolic prostaglandin E synthase
 - 3.4.3. Other prostaglandin E synthases
4. Catabolism of prostaglandin E₂ in fever
 - 4.1. Carrier-mediated cellular uptake
 - 4.2. Intracellular oxidation
5. Physiological implications
 - 5.1. A major role of transcriptional regulation in prostaglandin E₂ metabolism
 - 5.2. Differential regulation at three phases of lipopolysaccharide fever
 - 5.2.1. Febrile Phase 1
 - 5.2.2. Febrile Phases 2 and 3
6. Instead of conclusions
7. Acknowledgements
8. References

1. ABSTRACT

Prostaglandin (PG) E₂ is a principal downstream mediator of fever. It is synthesized in three steps catalyzed by phospholipase (PL) A₂, cyclooxygenase (COX), and terminal PGE synthase (PGES), where each catalytic activity is represented by multiple enzymes and/or isoenzymes. Inactivation of PGE₂ occurs primarily in the lungs and liver via carrier-mediated cellular uptake and enzymatic oxidation. The two principal carriers are PG transporter (PGT) and multispecific organic anion transporter (MOAT); the two principal PGE₂-inactivating enzymes are 15-hydroxy-PG dehydrogenase (15-PGDH) and carbonyl reductase (CR). Our data [Ivanov A. I. *et al. Am J Physiol Regul Integr Comp Physiol* 283, R1104-R1117 (2002); *ibid.* 284, R698-R706 (2003)] are used to analyze the relationship between transcriptional regulation of PLA₂, COX, PGES, PGT, MOAT, 15-PGDH, and CR, on one hand, and the triphasic febrile response of rats to lipopolysaccharide (LPS), on the other. It is concluded that LPS fever is accompanied by up-regulation of four PGE₂-synthesizing enzymes [secretory (s) PLA₂-IIA, cytosolic (c) PLA₂-alpha, COX-2, and microsomal (m) PGES-1] and down-regulation of all PGE₂ carriers and dehydrogenases studied (PGT, MOAT, 15PGDH, and CR). It is further concluded that different febrile phases employ different mechanisms to mount an increase in the PGE₂ level. *Phase*

1 involves transcriptional up-regulation of the couple COX-2 → mPGES-1 in the liver and lungs. *Phase 2* entails robust up-regulation of the major inflammatory triad sPLA₂-IIA → COX-2 → mPGES-1 throughout the body. *Phase 3* involves induction of cPLA₂-alpha in the hypothalamus and further up-regulation of sPLA₂-IIA and mPGES throughout the body. Importantly, *Phase 3* occurs despite a drastic decrease in the expression of COX-1 and -2 in both the brain and periphery, thus suggesting that transcriptional up-regulation of COX-2 is not an obligatory mechanism of PGE₂-dependent inflammatory responses at later stages. Of importance is also that LPS fever is accompanied by transcriptional down-regulation of PGE₂ transporters and dehydrogenases: 15-PGDH in the lungs at *Phase 1*; 15-PGDH and CR in the lungs at *Phase 2*; and PGT, MOAT, 15-PGDH, and CR in the liver and lungs at *Phase 3*. The transcriptional down-regulation of proteins involved in PGE₂ inactivation is a largely unrecognized mechanism of systemic inflammation. By increasing the blood-brain gradient of PGE₂, this mechanism likely facilitates penetration of PGE₂ into the brain. The high magnitude of up-regulation of mPGES and sPLA₂-IIA (1,260 and 130 fold, respectively) and that of down-regulation of 15-PGES (30 fold) during LPS fever makes these enzymes attractive targets for anti-inflammatory therapy.

Metabolism of prostaglandin E₂ in fever




Figure 1. Three steps of the PGE₂-synthesizing cascade. Substrates and products are shown in red (major pathway) or black (selected final products of alternative pathways); enzymes are shown in bold; explanatory signs are shown in italics. For abbreviation, see Section 2. (Modified from Ref. 31; published with permission of the American Physiological Society).

2. INTRODUCTION

Upon a systemic inflammatory challenge [e.g., with bacterial lipopolysaccharide (LPS) or pyrogenic cytokines, such as interleukin (IL)-1β and tumor necrosis factor (TNF)-α], the brain launches a powerful defense response: fever (1). Both clinical and experimental fevers are polyphasic. A single, bolus injection of LPS causes several sequential rises in body temperature, so-called febrile phases, each having its own thermoregulatory mechanism (2). Three phases (*Phases 1-3*) have been identified in the febrile response of the rat (3, 4) and mouse (5, 6), the species commonly used in research on inflammation and sepsis. In addition to having different thermoregulatory mechanisms (2), different febrile phases are accompanied by different sickness symptoms (e.g., hyperalgesia or allodynia at *Phase 1* vs. hypoalgesia at *Phase 2*; see Refs. 7-9) and are likely to be mediated by different cascades of endogenous mediators triggered by LPS (10). However, a common feature of all phases seems to be their dependence on prostaglandin (PG) E₂ (5, 10-14), which is widely accepted as the principal downstream mediator of LPS fever (15-17). During the febrile response to LPS, PGE₂ concentration is increased in the blood (10,

11), cerebrospinal fluid (18), and hypothalamus (12). Two main mechanisms responsible for such an increase, *viz.*, stimulation of PGE₂ synthesis and inhibition of its catabolism, are discussed in this review. While discussing these mechanisms, we will emphasize two points that have not received the deserved attention in the literature. Specifically, we will show that peripheral, blood-borne PGE₂ is important in triggering fever. We will also show the increases of PGE₂ in body fluids during different febrile phases are achieved by different mechanisms.

3. SYNTHESIS OF PROSTAGLANDIN E₂ IN FEVER

3.1. Three steps of the enzymatic cascade

The synthesis of PGE₂ occurs in three steps (19) schematically presented in Figure 1. First, arachidonic acid (AA) is released from membrane phospholipids via action of phospholipase (PL) A₂ (19-21). Second, AA is converted to PGG₂ and then to PGH₂ by cyclooxygenase (COX) (19, 22). Third, PGH₂ is isomerized to PGE₂ by terminal PGE synthase (PGES) (23, 24). Each step of this cascade can be catalyzed by several nonhomologous enzymes and/or multiple isoforms of the same enzyme. Thus, the mammalian PLA₂ family consists of more than a dozen members, both cytosolic (c) and secretory (s) (20, 21). Two COX isoforms, *i.e.*, COX-1 and COX-2, have been firmly identified (22). The PGH₂ → PGE₂ isomerizing activity is attributed to several PGES enzymes (23, 24), both in cytosol (cPGES) and bound to intracellular membranes, so-called microsomal PGES (mPGES).

An important feature of the PGE₂-synthesizing cascade is a functional coupling between selective isoforms of the enzymes at different steps of the cascade (21, 24-26). Examples of such a coupling are presented below. The functional coupling plays an important role in selective distribution of AA and its metabolites between the PGE₂ pathway vs. several alternative eicosanoid pathways. Under basal conditions, the rate of PGE₂ synthesis in various cells is limited by both the release of AA by PLA₂ and the consumption of AA by alternative pathways (19, 27). Along with robust activation all three steps of PGE₂ synthesis, inflammatory stimuli cause a preferential redistribution of AA and its metabolites toward the PGE₂ pathway (28, 29).

3.2. Step 1: phospholipases A₂

The superfamily of the PLA₂ enzymes (all of which hydrolyze the *sn*-2 ester bond of membrane phospholipids; see Refs. 20, 21) is divided into four classes: calcium-dependent cPLA₂; sPLA₂; calcium-independent cPLA₂; and platelet-activating factor (PAF)-acetylhydrolase (21). Since two later classes are unlikely to play a significant role in PGE₂ synthesis, they are not discussed in this review.

3.2.1. Calcium-dependent cytosolic phospholipases A₂

The group of calcium-dependent cPLA₂ contains three isoenzymes expressed abundantly in various mammalian tissues: cPLA₂-α, cPLA₂-β, and cPLA₂-γ, of which the alpha form is the most studied (21).

Metabolism of prostaglandin E₂ in fever

In resting cells, the inactive form of cPLA₂-alpha is present in cytosol. Upon stimulation by inflammatory agents, cPLA₂-alpha becomes rapidly (within minutes) phosphorylated and translocates to the Golgi complex, endoplasmic reticulum, and nuclear envelope (20, 21), *i.e.*, into close vicinity of the downstream PGE₂-synthesizing enzymes (see Sections 3.3, 3.4). Translocation to intracellular membranes results in release of fatty acids, predominantly AA. Besides posttranslational activation, LPS has been shown to cause a modest (up to 3 fold) transcriptional up-regulation of cPLA₂-alpha in cultured rat liver macrophages (30) and in the rat hypothalamus *in vivo* (31). To what extent this transcriptional up-regulation contributes to the elevated activity of the enzyme remains unclear. Many authors consider cPLA₂-alpha a key enzyme for PG production during inflammation (25, 32, 33). Indeed, immune cells generated from cPLA₂-alpha knockout mice show a marked reduction in PG synthesis (34). Furthermore, both genetic (35) and pharmacological (36) blockage of cPLA₂-alpha attenuates LPS- and zymozan-induced lung injury in rats. The indispensability of this enzyme for PGE₂ synthesis in stimulated immune cells and its rapid activation in inflammation suggest an involvement of cPLA₂-alpha in LPS fever. Yet, a first attempt to reveal an involvement of cPLA₂-alpha in the febrile response to LPS by using the knockout mouse produced negative results (37). This is rather surprising, because Bosetti and Weerasinghe (38) have shown that the expression of COX-2 is selectively down-regulated in the same knockout. Furthermore, the authors have not found any compensation by sPLA₂ or calcium-independent-PLA₂ for the lack of cPLA₂-alpha in this model (at least under basal conditions), thus suggesting that cPLA₂-alpha is selectively coupled with COX-2, and that its role as a supplier of AA for COX-2 cannot be taken by other PLA₂ enzymes.

3.2.2. Secretory phospholipases A₂

In mammals, the rapidly expanding sPLA₂ family now includes ten enzymes known as groups IB, IIA, IIC, IID, IIE, IIF, III, V, X, and XII (21). The cellular localization and the principal mechanism of activation of sPLA₂ differ from those of cPLA₂. A substantial fraction of sPLA₂ (all groups) is secreted into the extracellular space to release AA from the outer leaflet of plasma membrane (20, 21). The major mechanism of sPLA₂ activation in stimulated cells is transcriptional up-regulation (20, 21, 39).

One of the better-known members of the sPLA₂ family, sPLA₂-IIA, was initially described in the synovial fluid of patients with rheumatoid arthritis (40). Not surprisingly, the expressional regulation of this isoform during experimental and clinical inflammation has attracted keen attention. Increased blood levels of sPLA₂-IIA and its transcriptional up-regulation have been repeatedly demonstrated in patients with systemic inflammation and in laboratory animals with LPS-induced shock (for review, see Refs 40, 41). In the rat, large, shock-inducing doses of LPS (up to 10 mg/kg) induce up-regulation of sPLA₂-IIA in a variety of peripheral organs (42-44) and the brain (43). Importantly, functional coupling with COX-2 has been

proposed for sPLA₂-IIA and its homolog sPLA₂-V (20, 25, 45).

We have found a strong up-regulation of sPLA₂-IIA during the polyphasic febrile response to a mild (50 microg/kg) dose of LPS in rats (31). Interestingly, the up-regulation of sPLA₂-IIA transcription was readily detectable in both the brain and periphery (liver and lungs), but the magnitude of the up-regulation was much higher in the hypothalamus (133 fold) than in the peripheral, LPS-processing organs (up to 9 fold). In the same study, we failed to detect any effect of LPS on expression of the homologous enzyme sPLA₂-V (31). The genes encoding sPLA₂-IIA and -V are located on the same chromosome; their transcriptional regulation is thought to be coordinated (21, 46); and their functional redundancy is evident in cell culture experiments (20, 25, 46). However, a dissociation in the expression of sPLA₂-IIA and -V was found by Sawada *et al.* (44) in two *in-vivo* models of LPS shock. Based on these findings (31, 44), the roles of sPLA₂-IIA and -V in inflammation are likely to be different and possibly tissue- and/or species-specific. Different responses of these two enzymes to several inflammatory stimuli have been also observed in the recent study by Hamaguchi *et al.* (47).

Recently, three novel sPLA₂ isoforms were found to be over-expressed in peripheral tissues (isoforms IID, IIE, and IIF) and the brain (isoforms IIE and IIF) at a late stage of LPS shock in mice (47-50). Being highly cationic, the IIA, IID, and IIE isoforms bind to negatively-charged molecules of glypican, a heparan sulfate-containing protein of the cell membrane. Such binding to glypican augments the release of AA from the cell membrane, thus representing an additional mechanism regulating the activity of these sPLA₂ isoforms (21, 49, 50). Small cationic proteins annexins (lipocortins)-I and -V compete with sPLA₂ of these groups for negatively-charged binding sites on the membrane (51, 52). Because annexins attenuate experimental fevers in rodents (53, 54), the sPLA₂-mediated, glypican-binding-dependent augmentation of AA release can be speculated to play a role in the febrile response.

Whereas the abovementioned groups IIA, V, IID, IIE, IIF, and V are responsive to inflammatory stimuli, other members of the sPLA₂ family are not (20, 21).

3.3. Step 2: cyclooxygenases

Formerly known as PGH synthase, COX catalyzes the double reaction of cyclization and peroxidation of AA producing sequentially PGG₂ and PGH₂ (Figure 1; also see Refs. 19, 22). Two isoforms of this enzyme, COX-1 and COX-2, are well characterized (22). Recently, a variant of COX-1 (named COX-3, or COX-1b) was cloned (55). Although COX-1 and -2 share ~60% of their sequences and catalyze the same reaction, they are differentially regulated and have different physiological functions (22). The reasons for the different functional properties of COX-1 and -2 may include subtle kinetic differences (*viz.*, different thresholds for hydroperoxide activation and different sensitivities to allosteric inhibition by high concentrations of AA; see Refs.




Figure 2. Dynamic changes of transcriptional regulation of COX-1 and COX-2 during the triphasic febrile response to intravenous LPS (50 microg/kg) in the liver, lungs, and hypothalamus. For each organ, point 1 (0 h) corresponds to the basal conditions (relative expression of both enzymes is ~100%); point 2 (0.5 h post LPS) corresponds to the maximal rate of body temperature change at *Phase 1* of the triphasic response to intravenous LPS; next point (1 h) corresponds to the maximal rate of body temperature change at *Phase 2*; and the end point (5 h post-LPS) corresponds to *Phase 3*. In all three organs the levels of both messages dramatically decrease (moves downward for COX-1 and to the left for COX-2) between *Phases 2* and *3*. In saline-treated rats (not shown), all points (0, 0.5, 1, and 5 h) are located close to each other, and their abscissas and ordinates are all equal ~100%. (This original figure uses data reported in Ref. 31.)

56, 57), the difference in coupling with other PGE₂-synthesizing enzymes (covered elsewhere in this review), and a possible difference in the distribution of the two isoforms between the endoplasmic reticulum, perinuclear envelope, and nuclear matrix (58, 59). Although the latter difference is relative, perhaps cell-specific, and may even have methodological causes, COX-1 is often viewed as a mostly extranuclear form, whereas COX-2 is often considered mostly intranuclear (59, 60).

3.3.1. Cyclooxygenase-1

COX-1 is expressed constitutively in most tissues, where it plays a wide range of housekeeping roles (22, 61). Although a low-magnitude (2-to-3-fold) induction of COX-1 by mitogens and growth factors was found in several studies *in vitro* (for review, see Ref. 61) and confirmed in LPS shock (62) and polymicrobial peritonitis (63) *in vivo*, this isoform is generally considered resistant to transcriptional up-regulation (22, 61). A recent study shows that the COX-1 variant COX-1b also does not appear to be induced by acute inflammatory stimulation (64).

Studies involving selective pharmacological inhibition of COX-1 found no role for this isoform in *Phases 2* and/or *3* of LPS fever in rats (65, 66) and guinea pigs (14), but did not decisively answer whether COX-1 is involved in *Phase 1*. Several methodological conditions (non-stressful injection of LPS, near-neutral ambient temperature, *etc.*) are required to study febrile *Phase 1* (4), but those conditions were not satisfied in the studies conducted (65, 66). The published work using COX-1 and COX-2 knockout mice (67) did not shed light on this issue, because LPS was administered in such a way that pronounced stress hyperthermia occurred and completely masked *Phase 1* of the response. We have eliminated this shortcoming by administering LPS intravenously in a non-stressful way (6). Our in-progress study (Steiner A. A, A. Y. Rudaya & A. A. Romanovsky) involving such a non-stressful administration of LPS shows that *Phase 1* is missing in COX-2 knockout mice, whereas it is preserved (and possibly even exaggerated) in COX-1 knockouts. This observation suggests that *Phase 1* is mediated entirely by COX-2, and that COX-1 is uninvolved.

An interesting phenomenon was observed in our recent study (31). In addition to the expected finding that expression of COX-1 is unchanged during *Phases 1* and *2* of triphasic LPS fever in rats, we found that the level of COX-1 mRNA decreased in the liver (7 fold) and lungs (3 fold) and showed a strong tendency for a decrease in the hypothalamus at *Phase 3* (Figure 2). This finding agrees with data of Liu *et al.* (68) and Devaux *et al.* (69) showing down-regulation of the COX-1 gene in the liver, lungs, and heart of rats challenged with shock-inducing doses of LPS. In our study (31), the decrease of COX-1 mRNA to below its basal level occurred concurrently with the decline of COX-2 mRNA from the peak of its response. Indeed, Figure 2 shows that when the ordinate (COX-1 expression) decreases (moves downward) from the 1-h point to the 5-h point, the abscissa (COX-2 expression) also decreases (moves from right to left) in all tissues studied. The simultaneous suppression of both genes suggests a common

Metabolism of prostaglandin E₂ in fever

mechanism for their transcriptional down-regulation at the later stages of the febrile response. Such a mechanism may involve activation of the peroxisome proliferator-activated receptors, which are considered negative regulators of the inflammatory response (70). A potent endogenous agonist of these receptors, 15-deoxy-delta^{12,14}-PGJ₂ (15d-PGJ₂), was recently shown to suppress LPS-induced COX-2 expression in cultured macrophage-like cells (71) and in rat hypothalamus (72); it was also shown to suppress LPS-induced fever in rats (72). This natural metabolite of PGD₂ is synthesized via a COX-dependent pathway and may, therefore, constitute a negative feedback mechanism for COX expression (70).

3.3.2. Cyclooxygenase-2

Because COX-2 is by far the most studied enzyme of the PGE₂-synthesizing cascade, we will describe its role in fever briefly and refer the reader to recent reviews published in this special issue of the *Frontiers in Bioscience* (73) and elsewhere (17, 22, 61, 74). In contrast to COX-1, COX-2 transcript is barely detectable in most quiescent cells, but it is robustly up-regulated by inflammatory stimuli (22, 61, 74). The major role of COX-2 in LPS fever has been shown by several recent studies involving pharmacological analyses (14, 65, 66) and using gene knockouts (67). Studies of the LPS-induced COX-2 expression *in vivo* (for review, see Ref. 73) confirm such a role: intravenous LPS drastically up-regulates COX-2 mRNA and immunoreactivity in the brain vasculature and the meninges, while leaving COX-1 expression unchanged (75-77). COX-2 expression in the brain is also stimulated by intravenous IL-1beta and TNF-alpha (78, 79), but not by IL-6 (76). Interestingly, different pyrogens and different doses of the same pyrogen up-regulate expression of COX-2 in different cells in the brain (80, 81). A subpyrogenic dose of LPS (0.1 microg/kg) induces COX-2 expression selectively in brain perivascular macrophages. Higher doses of LPS up-regulate expression of this enzyme in both perivascular macrophages and endotheliocytes. Over-expression of COX-2 in the brain in response to a wide range of doses of IL-1beta is restricted to perivascular macrophages.

Also of interest are the relative contributions of brain-synthesized vs. peripherally produced PGE₂ to the febrile response, especially at the onset of the response. The dynamics of the COX-2 mRNA expression in LPS-processing organs (liver and lungs) and the hypothalamus in the dynamics of triphasic LPS fever was studied in our recent work (31). The kinetics of COX-2 up-regulation by LPS *in vivo* was found to be remarkably fast. Already at the beginning of the febrile *Phase 1* (~30 min after LPS injection), the level of transcript was increased both in the periphery and in the brain. Importantly, the *Phase-1*-associated response of the COX-2 gene was much stronger in the peripheral organs (17 fold over-expression in the liver and 5 fold over-expression in the lungs) than in the brain (3 fold over-expression) — in line with the idea of peripherally produced PGE₂ playing a role in fever (10, 11, 82, 83). In all the tissues studied, the induction of COX-2 peaked during *Phase 2* and then rapidly declined simultaneously with downregulation of COX-1 (Figure 2).

Although the expression of COX-2 throughout the body (at least, in the liver, lungs and hypothalamus) was drastically decreasing from *Phase 2* to *Phase 3*, (e.g., from 15 fold over-expression to below the basal level in the lungs), expression of other enzymes of the PGE₂-synthesizing cascade (*viz.*, hepatic sPLA₂-IIA and mPGES-1, hypothalamic cPLA₂-alpha, sPLA₂-IIA, and mPGES-1) was skyrocketing (e.g., from 280 to 1,260 fold over the basal level for hepatic mPGES), and body temperature was rising.

Such a discrepancy between the expression of COX-2 and the dynamics of the PGE₂-mediated febrile response suggests that to consider the level of COX-2 mRNA as a measure of PGE₂ concentration (as done in many studies) is an oversimplification. The discrepancy observed in our study (31) agrees well with the lack of correlation between the tissue level of COX-2 protein and the concentration of PGE₂ found by Inoue *et al.* (18) and with the observation by Imai-Matsumura *et al.* (84) that some LPS-treated pregnant rats have the number of COX-2-positive brain cells well within the range observed in their non-pregnant counterparts but still exhibit a drastically blunted PGE₂ response to LPS. These data suggest that the reactions catalyzed by COX (Figure 1, step 2) are not rate-limiting within the PGE₂-synthesizing cascade. Different opinions on this issue can be found in a recent discussion (85).

3.4. Step 3: terminal synthases

The final step of the PGE₂-synthesizing cascade is a nonoxidative rearrangement of the COX product, PGH₂ into PGE₂ (23, 24; Figure 1). Although this isomerization can occur nonenzymatically, living cells produce PGE₂ *via* a catalytic reaction using reduced glutathione as an obligatory cofactor (23, 24). This reaction is attributed to several newly discovered proteins, PGES. Jakobsson *et al.* (86) identified the first mPGES, a 16-kD member of the so-called MAPEG (for membrane-associated proteins involved in eicosanoid and glutathione metabolism) superfamily; this protein is now designated as mPGES-1. A different PGES was found by Tanioka *et al.* (87) in the cytosol of various mammalian cells and is known as cPGES. More recently, Tanikawa *et al.* (88) purified and cloned one more mPGES; this protein belongs to the thioredoxin family and is termed mPGES-2. In addition, mu2 and mu3 representative of the mu class of glutathione-S-transferase (GST) have been identified as potential PGES (89).

In-vitro COX-PGES co-expression experiments have shown that cPGES is functionally coupled with COX-1 (which is localized preferentially outside the nucleus, at least according to some authors, see Refs. 59, 60); this couple is responsible for basal synthesis of PGE₂ and for the immediate release of PGE₂ in response to calcium-mobilizing agents (87). In contrast, mPGES-1 strongly prefers the mostly nuclear isoform COX-2 over COX-1; the COX-2-mPGES-1 couple is crucial for the delayed synthesis of PGE₂ in response to proinflammatory stimuli (26, 28). The other microsomal enzyme, mPGES-2, may contribute to both immediately and delayed prostaglandin




Figure 3. Schematic representation of coupling of different PGES with COX-1 and COX-2 in relationship to the intracellular localization of the enzymes involved (for discussion, see Section 3.4). The question marks refer to the less established relationships.

responses and can couple with both COX isoforms (90); which of the two COX isoforms is preferred by mPGES-2 and to what extent remains unclear. For different PGES, the relationship between their preferential localization and preferential (or even exclusive) coupling with different COX isoforms is schematically presented in Figure 3.

3.4.1. Microsomal prostaglandin E synthase-1

Because of its strong preferential coupling with COX-2, mPGES-1 is probably the most important PGES in inflammation-associated PGE₂ synthesis. In rats, high (120-400 microg/kg) doses of LPS increase mPGES-1 mRNA and protein levels in the brain and many peripheral organs, including the lungs and spleen (26, 91). Yamagata *et al.* (92) reported the induction of mPGES-1 transcript by LPS in many areas of the rat brain. The message was localized in brain vasculature, and the protein was abundant in the perinuclear envelope of endothelial cells, where mPGES-1 was co-localized with COX-2 (92). Ek *et al.* (93) also found co-induction of mPGES-1 and COX-2 by IL-1beta in brain vascular cells, presumably endotheliocytes and perivascular macrophages. Engblom *et al.* (94) demonstrated a crucial role of mPGES-1 in LPS fever by using recently developed (95, 96) knockout mice.

In our recent study of LPS-induced fever in rats, we found strong transcriptional up-regulation of the mPGES-1 gene in peripheral LPS-processing organs and in the brain (31). The dynamics of this up-regulation was tissue-specific. In the liver and lungs, the level of mPGES-1 transcript was already increased at *Phase 1*; in the hypothalamus, it was not induced until *Phase 2*. Remarkable features of the mPGES-1 response were its magnitude and duration. Indeed, the expression of this gene was up-regulated more than 1,200 fold in the liver and more than 30 fold in the lungs and hypothalamus and persisted for several hours after a single LPS injection.

Even at the times when COX-2 expression had returned to its baseline, mPGES-1 remained over-expressed. The most terminal position in the PGE₂-synthesizing cascade, the highest magnitude of up-regulation among all PGE₂-synthesizing enzymes studied, and the long duration of its upregulation makes mPGES an attractive target for antipyretic/anti-inflammatory therapy (31). The abovementioned fact that mPGES is strongly up-regulated when expression of COX-2 declines adds to its attractiveness as a pharmacological target.

3.4.2. Cytosolic prostaglandin E synthase

According to Tanioka *et al.* (87), LPS, IL-1beta, and TNF-alpha have no effect on the level of cPGES mRNA in cultured human and murine gliocytes, epitheliocytes, and fibroblasts. Neither do these pyrogens affect cPGES expression in rat tissues *in vivo*, with the exception of the brain, where a several-fold increase in the level of cPGES transcript was found at a late stage of LPS shock. When using a lower dose of LPS, we did not see any changes in the expression of cPGES in the liver, lungs, or hypothalamus during LPS fever in rats (31). As shown by these data and suggested by the exclusive coupling of cPGES with COX-1 (Figure 3), this PGES is likely uninvolved in inflammatory PGE₂ synthesis.

3.4.3. Other prostaglandin E synthases

Not much is known about involvement of mPGES-2 and GST-mu in inflammation and fever. Murakami *et al.* (90) have shown that mPGES-2 expression in epithelial and fibroblastic cells is insensitive to IL-1beta and TNF-alpha and just marginally increased in mice liver during endotoxemia (90). As for the mu class of GST, one of them, *i.e.*, GST-mu subunit 6 (Yb3), is abundant in the hypothalamus (97) — the brain's febrigenic "center". Studies involving selective inhibitors and knockout animals are needed to determine involvement of different PGES in fever.

4. CATABOLISM OF PROSTAGLANDIN E₂ IN FEVER

PGE₂ is a rapidly acting, short-lived mediator. Its physiological effects (*e.g.*, fever following an intrabrain administration) typically have a latent period of a few minutes and duration of tens of minutes (for examples of PGE fever curves, see Refs. 98-100). The half-life of exogenous PGE₂ in the blood plasma is less than 60 s (101). Rapid inactivation of blood-borne PG in the lungs, kidney, and liver (102, 103) is a mechanism for changing the blood level of these short-lived molecules. It is noteworthy that PGE₂ is not catabolized in the brain of adult mammals (104). To be inactivated, brain PGE₂ has to escape the brain tissue (supposedly via the choroid plexus) and enter the blood (105). A high brain-to-blood PGE₂ gradient has been shown to facilitate the escape of PGE₂ from the brain, whereas a low gradient counteracts such an escape (106). Hence, by changing the blood concentration of PGE₂, the processes of transport and catabolism of PGE₂ in peripheral organs can affect the level of PGE₂ not only in peripheral tissues, but also in the brain. It is tempting, therefore, to speculate that catabolism of PGE₂ in peripheral tissues can be used by the body to regulate the febrile and other

Metabolism of prostaglandin E₂ in fever

physiological responses driven by both peripheral and central PGE₂. Since little or no PGE-catabolizing activity can be found in the blood or associated with the cell surface, a two-step model of metabolic clearance of PGE₂ implies its carrier-mediated uptake across the plasma membrane followed by its intracellular enzymatic oxidation (107-109).

4.1. Carrier-mediated cellular uptake

Newly synthesized molecules of PG readily leave the cell due to a passive diffusion of the protonated PG species, which prevail in a mildly acidic cytosolic environment (108). In the extracellular space (pH 7.4) they became anionic, and this charge greatly inhibits the ability of PG to cross the cell membrane. Indeed, several studies reported that the ability of PG to permeate in erythrocytes, kidney epithelial cells, and other cultured cells is poor (for review, see Refs. 108, 109). Almost three decades ago, Bito *et al.* (106, 107) provided compelling evidence for the existence of carrier-mediated PG transport across the plasma membrane. In fact, this transport is the rate-limiting step of PGE₂ inactivation, at least in the lungs (110). The two most specific transmembrane carriers of PGE₂ are PG transporter (PGT; a.k.a. *matrin*; Ref. 111) and multispecific organic anion transporter (MOAT; Ref. 112). Other putative PG transporters have been recently found in the organic anion transporter and organic cation transporter protein families (113).

PGT is the first discovered and the best characterized transporter. It is widely expressed in various peripheral tissues and in the brain of several mammalian species and humans (for review, see Refs. 108, 109). Interestingly, in the polarized kidney and prostate epithelial cells, PGT is localized at the apical membrane, where it facilitates PG transport in the apical-to-basolateral direction (108, 114). If PGT has similar polarized distribution in choroid plexus epithelial cells, it is perfectly positioned to facilitate efflux of PGE₂ from cerebrospinal liquid into the blood.

Little is known about regulation of transmembrane transport of PGE₂ in fever and systemic inflammation. One study showed that PGE₂ uptake was inhibited in the rabbit uvea by topical application of LPS (115), whereas another study failed to detect any effect of IL-1beta on PGT expression in human endothelial cells *in vitro* (116). Recently we found that expression of the two major transmembrane carriers of PGE₂ (*viz.*, PGT and MOAT) is down-regulated during the triphasic febrile response to a mild dose of systemic LPS in rats (117). Expression of both transporters was inhibited at the transcriptional level in the liver and lungs but not in hypothalamus, and this effect was evident only during febrile *Phase 3*. The level of PGT mRNA in the hypothalamus showed a tendency to increase during *Phases 2* and *3*. More recently, Matsumura *et al.* (118) presented *in-situ* hybridization data showing that PGT mRNA was weakly expressed in the brain of intact rats, but remarkably induced in the arachnoidal membrane and in blood vessels of the subarachnoidal space at late stages (5-48 h) of the response to systemic LPS administration. However, PGT

was expressed only in a fraction of COX-2-positive endothelial cells. These data confirm that PGT is not essential for the release of PGE₂ from cells. Rather PGT is involved in the uptake of PGE₂ from the cerebrospinal fluid and in its excretion into the blood. This mechanism may limit the febrile response.

4.2. Intracellular oxidation

Intracellular catabolism of PGE₂ consists of several subsequent reactions, of which the first reaction, enzymatic oxidation of the 15-hydroxyl group, is crucial because it leads to the great reduction of biological activities (119). This reaction is catalyzed by 15-hydroxy-PG dehydrogenase (15-PGDH; formerly known as 15-PGDH type I) and carbonyl reductase (CR; formerly, 15-PGDH type II) (see Refs. 120, 121). CR also possesses the 9-keto-reductase activity and thus inactivates PGE₂ by converting it to PGF_{2alpha} (122), a much less potent inducer of fever and other inflammatory symptoms (16, 123). Both enzymes are widely distributed in peripheral tissues but are weakly expressed in mammalian brain (121, 124). This is not surprising, because the brain of adult mammals is virtually devoid of PG-oxidizing activity (104, 124). The physiological importance of 15-PGDH is supported by the fact that its genetic deletion (125) or transcriptional down-regulation (*e.g.*, as a result of thermal injury; see Ref. 126) leads to increases in the blood and/or tissue levels of PGE₂.

Surprisingly, there are only a few reports of the expressional regulation of 15-PGDH and CR by inflammatory agents. Both IL-1beta and TNF-alpha were reported to decrease the expression of 15-PGDH and inhibit PGE₂ catabolism in cultured human trophoblasts (127, 128), whereas shock-inducing doses of LPS were shown to inhibit the expression of pulmonary 15-PGDH and catabolism of PGE₁ and PGE₂ *in vivo* (129-131). Our study of 15-PGDH and CR expression during a triphasic LPS fever in rats demonstrated a rapid (starting during *Phase 1*) and dramatic (up to 26 fold) decrease in 15-PGDH mRNA level in the liver and lungs; we also found a similar, although less pronounced, down-regulation of CR expression in the liver and lungs (117). Since the half-life of the 15-PGDH protein is on the order of tens of minutes (132), its dramatic transcriptional down-regulation should rapidly decrease the level of the active enzyme, and thus contribute to the increased PGE₂ level during LPS fever.

The transcriptional downregulation of PGE₂ transporters and inactivating enzymes found in our recent study (117) provides new explanations for the experimental phenomenon observed by Davidson *et al.* (133). These authors reported that intravenous administration of LPS, IL-1beta, or TNF-alpha in rabbits readily facilitates PGE₂ entry from the peripheral circulation into the brain. The authors hypothesized that this phenomenon reflects a disruption of the blood-brain barrier (BBB) in systemic inflammation. Based on our findings (117), we suggest that an accelerated influx of circulating PGE₂ into the brain during fever may occur even if the integrity of the barrier is uncompromised. The simultaneous, drastic transcriptional down-regulation of four major PGE₂-inactivating enzymes in the liver and lungs is likely to increase the blood

Metabolism of prostaglandin E₂ in fever




Figure 4. Schematic summary of our recent studies (31, 117). Up-regulation of a gene involved in PGE₂ metabolism in LPS-treated rats at a given febrile phase (compared to the corresponding saline-treated rats) is shown in red; down-regulation is shown in white; gray represents no statistically significant changes. +, statistically significant up-regulation of a gene at the given febrile phase compared to the preceding phase; -, statistically significant down-regulation of a gene at the given febrile phase compared to the preceding phase. Note that some genes (COX-2 in the liver and hypothalamus and mPGES-1 in the lungs) are up-regulated at Phase 3 as compared to their expression in saline-treated rats, but down-regulated as compared to their expression at Phase 2. (Modified from Ref. 31; published with permission of the American Physiological Society.)

concentration of PGE₂ and, therefore, the blood-to-brain PGE₂ gradient. Yet, the expression of PGE₂ carriers in the hypothalamus *per se* remains unaltered (or even increased, see Ref. 118) during fever. In the presence of normally expressed or over-expressed PGE₂ carriers, the increased blood-brain PGE₂ gradient is likely to facilitate transport of circulating PGE₂ into the brain.

Our observation (117) that the febrile response to mild doses of LPS is accompanied by drastic (up to 26

fold) transcriptional down-regulation of PGE₂ transporters (PGT and MOAT) and its catabolizing enzymes (15-PGDH and CR) in the lungs and liver, but not the brain, may find clinical applications. We speculate that this down-regulation increases the blood-to-brain gradient of PGE₂ (decreases the brain-to-blood gradient) and is, therefore, likely to both facilitate penetration of PGE₂ into the central nervous system and prevent its elimination from the brain. This largely unrecognized mechanism may constitute a novel target for antipyretic and anti-inflammatory therapy. What adds to the attractiveness of this target is that tissue expression of PGE₂ transporters and dehydrogenases is suppressed most dramatically at the time when COX-2 expression is declined.

5. PHYSIOLOGICAL IMPLICATIONS

5.1. A major role of transcriptional regulation in prostaglandin E₂ metabolism

Transcriptional up-regulation is a major mechanism of activation for several enzymes involved in PG metabolism as suggested by the existence of binding sites for a variety of proinflammatory transcription factors (*e.g.*, AP-2, NF-kappaB, and cAMP regulatory binding protein) in the 5'-flanking region of several enzymes involved, including cPLA₂-alpha, sPLA₂-IIA and -V (20, 21, 39), and COX-2 (22). As reviewed in this paper, a large amount of data has been accumulated showing that LPS, IL-1beta and TNF-alpha, induce massive release of PGE₂ *via* transcriptional up-regulation of PLA₂, COX-2, and/or mPGES-1 *in vitro* and *in vivo*. On the other hand, transcriptional down-regulation is likely to be a major mechanism of inactivation of PGE₂ transporters and catabolizing enzymes. Genomic sequences of human PGT (134), mouse 15-PGDH (135), and human CR (120) all contain sequences for Sp1 transcription factor binding. LPS and TNF-alpha decrease DNA-binding activity of Sp1 and inhibit Sp1-mediated gene expression (136, 137). Hence, inactivation of constitutive transcription factor Sp1 by LPS or LPS-induced cytokines may be a common mechanism for transcriptional down-regulation of PGT, 15-PGDH, and CR in fever.

5.2. Differential regulation at three phases of lipopolysaccharide fever

Studies with pharmacological inhibition of PG synthesis (10, 13, 14, 66) and experiments in PGE receptor knockout mice (5) strongly suggest that PGE₂ is involved in all three febrile phases. However, they leave open the most intriguing question about pathogenesis of fever: how can the same mediator, PGE₂, bring about three different events, three febrile phases? Our recent studies (31, 117) show that each phase (and each underlying burst of PGE₂ concentration) is characterized by a distinct pattern of the transcriptional regulation of enzymes involved in PG synthesis and catabolism (Figure 4).

5.2.1. Febrile Phase 1

At Phase 1, the most remarkable event was a strong transcriptional up-regulation of the functional couple COX-2 → mPGES-1 in the peripheral LPS-processing organs (31). This event was accompanied by an up-

Metabolism of prostaglandin E₂ in fever

regulation of COX-2 transcription in the hypothalamus (31) and by down-regulation of 15-PGDH in the lungs (117). It can be suggested that the major mechanism of *Phase 1* is the synthesis of PGE₂ in the periphery. The proposed mediation of *Phase 1* by peripherally synthesized PGE₂ deserves special attention for two reasons.

First, *Phase 1*, which is characterized by a short duration (~1 h) and small magnitude (a few tenths of a degree) and which is very sensitive to experimental conditions (4) is considered by many unimportant. Yet, it possesses several remarkable features (see Ref. 138). This phase is by definition the earliest thermoregulatory event occurring in response to LPS, which makes it an important end-point measure for studying febrigenic signaling to the brain. Further, *Phase 1* is the only febrile phase characterized by the precise type of body temperature regulation (a narrow dead band) and not “contaminated” by poikilothermia (2); this makes it the only phase that truly satisfies the current definition of fever as an increase in the set point (139). *Phase 1* also has a unique biological significance: it is the only phase coupled with the so-called early sickness symptoms (*i.e.*, those symptoms that alarm the body about the forthcoming inflammation/infection and prepare it for an active response), such as hyperalgesia/allodynia and motor agitation (7-9). Finally, *Phase 1* is the only phase of polyphasic LPS fever that was proposed by Morimoto *et al.* (10) and is currently thought (9, 83, 140) to be triggered by afferent nerve fibers, specifically hepatic (141) vagal fibers. Indeed, hepatic fibers bear PG receptors of the EP3 type (142) [*i.e.*, one of the two types mediating *Phase 1* of LPS fever (5, 143, 144)], and activation of vagal afferents by cytokines is at least partially PG-mediated (142, 145).

The second reason for special attention to the mechanisms of *Phase 1* is that involvement of peripherally synthesized PG in fever goes against the prevailing views of the exclusive role of the centrally synthesized PG (15, 17). Interestingly, the important role of peripheral PGE₂ in fever was proposed in the late seventies by Dascombe and Milton (146) and re-stated in the eighties by at least three groups (11, 147, 148). However, several attempts to induce fever by intravenous or intracarotid PGE₂ or PGE₁ failed, as did attempts to detect PGE₂ in the cerebrospinal fluid or preoptic microdialysate following PGE₂ infusion into the carotid artery (for review, see Ref. 82). As a result, the idea of blood-derived PGE₂ playing an important role in fever has been either ignored [see, *e.g.*, Breder and Saper (149)] or plainly rejected [see, *e.g.*, Blatteis and Sehic (15) or Zhang and Rivest (17)] by many authors, including some of the early proponents (150). Our two studies [*viz.*, one showing a marked pyrogenic activity of PGE₂ administered intravenously as a complex with albumin (82) and the other demonstrating the expression of PGE₂-synthesizing enzymes in the liver and lungs — but not in the brain — during *Phase 1* of LPS fever (31)] and studies by others [showing that immune activation of vagal fibers is PG-dependent (142, 145)] have shifted the balance back in favor of the role of peripheral PGE₂ (for reviews, see 9, 83, 140). Perhaps a decisive argument in

this long-standing dispute, *i.e.*, demonstration of an attenuation of the febrile response by selective elimination of peripheral PGE₂, has been recently obtained by our group (Steiner A. A, A. I. Ivanov, A. Y. Rudaya, A. Dragic & A. A. Romanovsky, in progress). We have shown that intravenous anti-PGE₂ antibodies (that do not cross the BBB) strongly attenuate *Phase 1* of LPS-induced fever in rats.

5.2.2. Febrile Phases 2 and 3

Coming back to the transcriptional patterns of proteins involved in PGE₂ metabolism at different febrile phases (Figure 4), our studies (31, 117) showed that *Phase 2* of LPS fever in rats was characterized by a robust transcriptional up-regulation of the entire cascade, sPLA₂-IIA → COX-2 → mPGES-1, both in the periphery and in the brain. Importantly, up-regulation of these PGE₂-synthesizing enzymes was accompanied by transcriptional down-regulation of the major PGE₂-catabolizing enzymes (15-PGDH and CR) in the lungs. We speculate that intrabrain synthesis of PGE₂, peripheral synthesis of PGE₂, and inhibition of PGE₂ catabolism all contribute to this phase.

The most prominent events occurring at *Phase 3* were: synchronized down-regulation of PGE₂ transmembrane carriers (PGT and MOAT) and oxidizing enzymes (15-PGDH and CR) in both peripheral organs studied and further up-regulation of sPLA₂-IIA and mPGES-1 expression in the liver and hypothalamus. This phase also involved transcriptional up-regulation of cPLA₂-alpha. We speculate that both peripheral and central bursts of PGE₂ synthesis contribute to febrigenesis at *Phase 3*. We further conjecture that blood-borne PGE₂ more readily enters the brain at this phase due to the decreased carrier-mediated uptake and catabolism of PGE₂ in peripheral organs resulting in an increased blood-to-brain gradient for this mediator.

6. INSTEAD OF CONCLUSIONS

Although antipyretic remedies have been in use for millennia (151) and their mechanism of action (inhibition of PG synthesis) has been known for more than three decades (152), the research on PGE₂ metabolism in fever is now as vigorous as ever. A variety of new genetic, pharmacological, and molecular biological tools to study PGE₂ synthesis and catabolism have been developed within the last few years. As pointed out in Section 3, several enzymes and isoenzymes of the PGE₂ synthesizing cascade were discovered only recently. Even while this review was in preparation, several new studies were reported (*e.g.*, 37, 38, 94, 118). Clearly, not all conclusions that can be made today based on the data available will be immutable. Instead of making formal conclusions, we would like to identify some important observations and outline perspectives.

First, it has become clear that functional coupling between PLA₂ and COX and between COX and PGES (Figure 3) plays a key role in distributing AA and PGH₂ between the many eicosanoid pathways and between

Metabolism of prostaglandin E₂ in fever

different enzymes or isoenzymes of the same pathway. Because different enzymes or isoenzymes competing for the same substrate have different tissue distribution, intracellular localization, and mechanisms that regulate their activity, selective distribution of AA and PGH₂ between different synthetic pathways via coupling is likely to be functionally important. Although further research is needed to illustrate this statement with specific examples, we speculate that such selective distribution may explain a variety of physiological phenomena. For example, peripheral administration of the same dose of LPS (4, 7, 153), PAF (154), and possibly some pyrogenic cytokines causes fever at thermoneutrality (for current definitions, see Ref. 155) but hypothermia at subneutral ambient temperatures. The activation of cPLA₂ by LPS, PAF, or cytokines results in an accumulation of AA, which is converted by COX-2, lipoxygenase, and terminal synthases into several eicosanoids. Whereas some of these eicosanoids (e.g., PGE₂ and PGF_{2α}) are highly pyrogenic (16), others [e.g., PGD₂ (156), its metabolite 15d-PGJ₂ (72), and leukotrienes C₄ and D₄ (157)] can cause hypothermia. We hypothesized that at different ambient temperatures pyrogens may be preferentially delivered with blood flow to different target cells, in which proximal enzymes of eicosanoid synthesis are coupled with different terminal synthases (154).

Second, the idea that the febrile response is not a single, elementary, “homogeneous” act, but rather a complex, “heterogeneous” cascade of multiple processes has received strong support over the last three decades (see, e.g., Refs. 2, 3, 7-9, 158). It has also become clear that different febrile phases are mediated differently (10, 159). It is of no surprise, therefore, that our recent studies (31, 117) showed that different febrile phases are accompanied by different changes in the metabolism of the major downstream mediator of fever, PGE₂ (Figure 4). An important corollary of this finding is that different enzymes involved in PGE₂ metabolism are likely to be more effective targets at different stages of an inflammatory process and for acute vs. chronic inflammation. For example, inhibitors of COX-2 that do not cross the BBB should be highly effective at early stages of systemic inflammation (*Phase 1* of experimental fever); the same inhibitors are likely to be ineffective during the late stages (*Phase 3* of LPS fever), when PGE₂ synthesis is activated both outside and inside the BBB, and when a high blood-to-brain gradient of PGE₂ is maintained by down-regulation of PGE₂ transporters and catabolizing enzymes.

Third, the fact that both COX-1 and COX-2 enzymes are naturally down-regulated during later stages of fever (Figure 2) should be emphasized. This fact explains the reported lack of correlation between the tissue level of COX-2 (whether protein or mRNA) and either the concentration of PGE₂ or the intensity of a PGE₂-mediated response (height of fever) (18, 31, 84). This fact also allows us to speculate that certain housekeeping functions of COX-1 may suffer during systemic inflammation even when no COX-2 inhibitors are used. Last but not least, this fact suggests that other enzymes of PGE₂ synthesis (those that are up-regulated at the time when COX-2 is down-

regulated) may be better candidate targets for anti-inflammatory drugs.

Finally, our recent studies (31, 117) suggest several new antipyretic/anti-inflammatory targets. The most promising one is likely to be mPGES-1. Indeed, the over-expression of this enzyme during fever has the highest magnitude (1,260 fold), the longest duration (throughout all three febrile phases), and the widest tissue distribution (all organs studied, viz., the liver, lungs, and hypothalamus). In addition, because of the distal position of mPGES-1 in the PGE₂-synthesizing cascade (Figure 1), selective pharmacological blockade of this enzyme would affect only PGE₂ (a pro-inflammatory, “bad” PG) and would not decrease the production of anti-inflammatory, “good” PG such as the pair PGD₂ → 15d-PGJ₂. Another promising target is sPLA₂-IIA. Although its position in the PGE₂ synthesizing cascade is proximal, the transcriptional up-regulation of this enzyme during fever has a very high magnitude (130 fold) and duration (the longest febrile *Phases 2* and *3*). Finally, the transcriptional down-regulation of proteins involved in PGE₂ inactivation is a largely unrecognized mechanism of systemic inflammation. By increasing the blood-brain gradient of PGE₂, this mechanism likely facilitates penetration of PGE₂ into the brain and prevents its elimination from the brain. The high magnitude of down-regulation of the principal PGE₂-catabolizing enzyme 15-PGES (30 fold) during fever makes this protein another attractive target for anti-inflammatory therapy.

7. ACKNOWLEDGEMENTS

The authors' reviewed research has been supported by grants from the National Institutes of Health (NS 41233) and Bayer AG, Germany, to A.A.R. The graphic assistance and comments on the manuscript by F. E. Farmer are greatly appreciated. Drs. A. A. Steiner and V. F. Turek read an early version of the manuscript and provided important feedback. Dr. O. Shido acted as Reviewing Editor for this paper.

8. REFERENCES

1. Kluger, M. J: Fever: role of pyrogens and cryogens. *Physiol Rev* 71, 93-127 (1991)
2. Vybíral, S, M. Székely, L. Janský & L. Černý: Thermoregulation of the rabbit during the late phase of endotoxin fever. *Pflügers Arch* 410, 220-222 (1987)
3. Romanovsky, A. A, C. T. Simons & V. A. Kulchitsky: “Biphasic” fevers often consist of more than two phases. *Am J Physiol* 275, R323-R331 (1998)
4. Romanovsky, A. A, V. A. Kulchitsky, C. T. Simons & N. Sugimoto: Methodology of fever research: Why are polyphasic fevers often thought to be biphasic? *Am J Physiol* 275, R332-R338 (1998)
5. Oka, T, K. Oka, T. Kobayashi, Y. Sugimoto, A.

Metabolism of prostaglandin E₂ in fever

- Ichikawa, F. Ushikubi, S. Narumiya & C. B. Saper: Characteristics of thermoregulatory and febrile responses in mice deficient in prostaglandin EP1 and EP3 receptors. *J Physiol* 551, 945-954 (2003)
6. Rudaya, A. Y., A. A. Steiner & A. A. Romanovsky: Fever in the mouse: dose dependence of the febrile response of freely moving mice to IV lipopolysaccharide (LPS) at thermoneutrality (Abstract). *FASEB J* (2004, in press)
7. Romanovsky, A. A., V. A. Kulchitsky, N. V. Akulich, S. V. Koulchitsky, C. T. Simons, D. I. Sessler & V. N. Gourine: First and second phases of biphasic fever: two sequential stages of the sickness syndrome? *Am J Physiol* 271, R244-R253 (1996)
8. Romanovsky, A. A. & M. Székely: Fever and hypothermia: two adaptive thermoregulatory responses to systemic inflammation. *Med Hypotheses* 50, 219-226 (1998)
9. Romanovsky, A. A.: Signaling the brain in the early sickness syndrome: are sensory nerves involved? *Front Biosci* 9, 494-504 (2004)
10. Morimoto, A., N. Murakami, T. Nakamori & T. Watanabe: Evidence for separate mechanisms of induction of biphasic fever inside and outside the blood-brain barrier in rabbits. *J Physiol* 383, 629-637 (1987)
11. Rotondo, D., H. T. Abul, A. S. Milton & J. Davidson: Pyrogenic immunomodulators increase the level of prostaglandin E₂ in the blood simultaneously with the onset of fever. *Eur J Pharmacol* 154: 145-152 (1988)
12. Sehic, E., M. Székely, A. L. Ungar, A. Oladehin & C. M. Blatteis: Hypothalamic prostaglandin E₂ during lipopolysaccharide-induced fever in guinea pigs. *Brain Res Bull* 39, 391-399 (1996)
13. Scammell, T. E., J. D. Griffin, J. K. Elmquist & C. B. Saper: Microinjection of a cyclooxygenase inhibitor into the anteroventral preoptic region attenuates LPS fever. *Am J Physiol* 274, R783-R789 (1998)
14. Steiner, A. A., S. Li, J. Llanos-Q. & C. M. Blatteis: Differential inhibition by nimesulide of the early and late phases of intravenous- and intracerebroventricular-LPS-induced fever in guinea pigs. *Neuroimmunomodulation* 9, 263-275 (2001)
15. Blatteis, C. M. & E. Sehic: Prostaglandin E₂: a putative fever mediator. In: *Fever: Basic Mechanisms and Management*, 2nd ed. (Ed: Mackowiak P. A), Lippincott-Raven, Philadelphia, PA, pp. 117-145 (1997)
16. Milton, A. S.: Prostaglandins and fever. *Prog Brain Res* 113, 129-139 (1998)
17. Zhang, J. & S. Rivest: Is survival possible without arachidonate metabolites in the brain during systemic infection? *News Physiol Sci* 18, 137-142 (2003)
18. Inoue, W., K. Matsumura, K. Yamagata, T. Takemiya, T. Shiraki & S. Kobayashi: Brain-specific endothelial induction of prostaglandin E₂ synthesis enzymes and its temporal relation to fever. *Neurosci Res* 44, 51-61 (2002)
19. Smith, W. L., L. J. Marnett & D. L. DeWitt: Prostaglandin and thromboxane biosynthesis. *Pharmacol Ther* 49, 153-179 (1991)
20. Murakami, M., Y. Nakatani, G. Atsumi, K. Inoue & I. Kudo: Regulatory functions of phospholipase A₂. *Crit Rev Immunol* 17, 225-283 (1997)
21. Kudo, I. & M. Murakami: Phospholipase A₂ enzymes. *Prostaglandins Other Lipid Mediators* 68-69, 3-58 (2002)
22. Smith, W. L., D. L. DeWitt & R. M. Garavito: Cyclooxygenases: structural, cellular, and molecular biology. *Annu Rev Biochem* 69, 145-182 (2000)
23. Urade, Y., K. Watanabe & O. Hayaishi: Prostaglandin D, E, and F synthases. *J Lipid Mediators* 12, 257-273 (1995)
24. Murakami, M., Y. Nakatani, T. Tanioka & I. Kudo: Prostaglandin E synthase. *Prostaglandins Other Lipid Mediators* 68-69, 383-399 (2002)
25. Scott, K. F., K. J. Bryant & M. J. Bidgood: Functional coupling and differential regulation of the phospholipase A₂-cyclooxygenase pathways in inflammation. *J Leukoc Biol* 66, 535-541 (1999)
26. Murakami, M., H. Naraba, T. Tanioka, N. Semmyo, Y. Nakatani, F. Kojima, T. Ikeda, M. Fueki, A. Ueno, S. Ohishi & I. Kudo: Regulation of prostaglandin E₂ biosynthesis by inducible membrane-associated prostaglandin E₂ synthase that acts in concert with cyclooxygenase-2. *J Biol Chem* 275, 32783-32792 (2000)
27. Brash, A. R.: Arachidonic acid as a bioactive molecule. *J Clin Invest* 107, 1339-1345 (2001)
28. Dieter, P., R. Scheibe, P.-J. Jakobsson, K. Watanabe, A. Kolada & S. Kamionka: Functional coupling of cyclooxygenase 1 and 2 to discrete prostanoid synthases in liver macrophages. *Biochem Biophys Res Commun* 276, 488-492 (2000)
29. Matsumoto, H., H. Naraba, M. Murakami, I. Kudo, K. Yamaki, A. Ueno & S. Ohishi: Concordant induction of prostaglandin E₂ synthase with cyclooxygenase-2 leads to preferred production of prostaglandin E₂ over thromboxane and prostaglandin D₂ in lipopolysaccharide-stimulated rat peritoneal macrophages. *Biochem Biophys Res Commun* 230, 110-114 (1997)
30. Dieter, P., A. Kolada, S. Kamionka, A. Schadow & M. Kaszkin: Lipopolysaccharide-induced release of arachidonic acid and prostaglandins in liver macrophages:

Metabolism of prostaglandin E₂ in fever

Regulation by group IV cytosolic phospholipase A₂ but not group V and IIA secretory phospholipase A₂. *Cell Signaling* 14, 199-204 (2002)

31. Ivanov, A. I, R. S. Pero, A. C. Scheck & A. A. Romanovsky: Prostaglandin E₂-synthesizing enzymes in fever: differential transcriptional regulation. *Am J Physiol Regul Integr Comp Physiol* 283, R1104-R1117 (2002)

32. Hirabayashi, T. & T. Shimizu: Localization and regulation of cytosolic phospholipase A₂. *Biochim Biophys Acta* 1488, 124-138 (2000)

33. Sapirstein, A. & J. V. Bonventre: Specific physiological roles of cytosolic phospholipase A₂ as defined by gene knockouts. *Biochim Biophys Acta* 1488, 139-148 (2000)

34. Uozumi, N. & T. Shimizu: Roles for cytosolic phospholipase A₂α as revealed by gene-targeted mice. *Prostaglandins Other Lipid Mediators* 68-69, 59-69 (2002)

35. Nagase, T, N. Uozumi, S. Ishii, K. Kume, T. Izumi, Y. Ouchi & T. Shimizu: Acute lung injury by sepsis and acid aspiration: a key role for cytosolic phospholipase A₂. *Nat Immunol* 1, 42-46 (2000)

36. Nagase, T, N. Uozumi, T. Aoki-Nagase, K. Terawaki, S. Ishii, T. Tomita, H. Yamamoto, K. Hashizume, Y. Ouchi & T. Shimizu: A potent inhibitor of cytosolic phospholipase A₂, arachidonyl trifluoromethyl ketone, attenuates LPS-induced lung injury in mice. *Am J Physiol Lung Cell Mol Physiol* 284, L720-L726 (2003)

37. Sapirstein, A, H. Saito, T. A. Samad, E. O'Leary, S. J. Texel & J. V. Bonventre: Cytosolic phospholipase A₂ regulates lipopolysaccharide induction of cyclooxygenase-2 in the mouse brain (Abstract). Program #280.3. 2003 *Abstract Viewer/Itinerary Planner*. Washington, DC: Society for Neuroscience (2003)

38. Bosetti, F. & G. R. Weerasinghe: Brain cyclooxygenase-2 expression is transcriptionally and selectively down-regulated in cytosolic phospholipase A₂ knockout mice (Abstract). Program #448.5. 2003 *Abstract Viewer/Itinerary Planner*. Washington, DC: Society for Neuroscience (2003)

39. Andreani, M, J. L. Oliver, F. Berenbaum, M. Raymondjean & G. Berezziat: Transcriptional regulation of inflammatory secreted phospholipase A₂. *Biochim Biophys Acta* 1488, 149-158 (2000)

40. Vadas, P, J. Browning, J. Edelson & W. Pruzanski: Extracellular phospholipase A₂ expression and inflammation: the relationship with associated disease states. *J Lipid Mediators* 8, 1-30 (1993)

41. Bulger, E. M. & R. V. Maier: Lipid mediators in the pathophysiology of critical illness. *Crit Care Med* 28, N27-N36 (2000)

42. Nakano, T. & H. Arita: Enhanced expression of group

II phospholipase A₂ gene in tissues of endotoxin shock rats and its suppression by glucocorticoids. *FEBS Lett* 237, 23-26 (1990)

43. Lauritzen, I, C. Heurteaux & M. Lazdunski: Expression of group II phospholipase A₂ in rat brain after severe forebrain ischemia and in endotoxic shock. *Brain Res* 651, 353-356 (1994)

44. Sawada, H, M. Murakami, A. Enomoto, S. Shimbara & I. Kudo: Regulation of type V phospholipase A₂ expression and function by proinflammatory stimuli. *Eur J Biochem* 263, 826-835 (1999)

45. Naraba, H, M. Murakami, H. Matsumoto, S. Shimbara, A. Ueno, I. Kudo & S. Oh-ishi: Segregated coupling of phospholipases A₂, cyclooxygenases and terminal prostanoid synthases in different phases of prostanoid biosynthesis in rat peritoneal macrophages. *J Immunol* 160, 2974-2982 (1998)

46. Cho, W: Structure, function, and regulation of group V phospholipase A₂. *Biochim Biophys Acta* 1488, 48-58 (2000)

47. Hamaguchi, K, H. Kuwata, K. Yoshihara, S. Masuda, S. Shimbara, S. Oh-ishi, M. Murakami & I. Kudo: Induction of distinct sets of secretory phospholipase A₂ in rodents during inflammation. *Biochim Biophys Acta* 1635, 37-47 (2003)

48. Murakami, M, K. Yoshihara, S. Shimbara, G. Lambeau, M. H. Gelb, A. G. Singer, M. Sawada, N. Inagaki, H. Nagai, M. Ishihara, Y. Ishikawa, T. Ishii & I. Kudo: Cellular arachidonate-releasing functions and inflammation-associated expression of group IIF secretory phospholipase A₂. *J Biol Chem* 277, 19145-19156 (2002)

49. Murakami, M, K. Yoshihara, S. Shimbara, G. Lambeau, A. G. Singer, M. H. Gelb, M. Sawada, N. Inagaki, H. Nagai & I. Kudo: Arachidonate release and eicosanoid generation by group IIE phospholipase A₂. *Biochem Biophys Res Commun* 292, 689-696 (2002)

50. Murakami, M, K. Yoshihara, S. Shimbara, M. Sawada, N. Inagaki, H. Nagai, M. Naito, T. Tsuruo, T. C. Moon, H. W. Chang & I. Kudo: Group IID heparin-binding secretory phospholipase A₂ is expressed in human colon carcinoma cells and human mast cells and up-regulated in mouse inflammatory tissues. *Eur J Biochem* 269, 2698-2707 (2002)

51. Aarsman, A. J, G. Mynbeek, H. van den Bosch, B. Rothhut, B. Prieur, C. Comera, L. Jordan & F. Russo-Marie: Lipocortin inhibition of extracellular and intracellular phospholipases A₂ is substrate concentration dependent. *FEBS Lett* 219, 176-180 (1987)

52. Buckland, A. G. & D. C. Wilton: Inhibition of secreted phospholipases A₂ by annexin V. Competition for anionic phospholipid interfaces allows an assessment of the relative interfacial affinities of secreted phospholipase A₂. *Biochim*

Metabolism of prostaglandin E₂ in fever

Biophys Acta 1391, 367-376 (1998)

53. Davidson, J, R. J. Flower, A. S. Milton, S. H. Peers, & D. Rotondo: Antipyretic actions of human recombinant lipocortin-1. *Br J Pharmacol* 102, 7-9 (1991)

54. Palmi, M, M. Frosini, G. P. Sgaragli, C. Becherucci, M. Perretti & L. Parente: Inhibition of interleukin-1beta-induced pyresis in the rabbit by peptide 204-212 of lipocortin 5. *Eur J Pharmacol* 281, 97-99 (1995)

55. Chandrasekharan, N. V, H. Dai, K. L. Roos, N. K. Evanson, J. Tomsik, T. S. Elton & D. L. Simmons: COX-3, a cyclooxygenase-1 variant inhibited by acetaminophen and other analgesic/antipyretic drugs: cloning, structure, and expression. *Proc Natl Acad Sci USA* 99, 13926-13931 (2002)

56. Swinney, D. C, A. Y. Mak, J. Barnett & C. S. Ramesha: Differential allosteric regulation of prostaglandin H synthase 1 and 2 by arachidonic acid. *J Biol Chem* 272, 12393-12398 (1997)

57. Kulmacz, R. J, W. A. van der Donk & A. L. Tsai: Comparison of the properties of prostaglandin H synthase-1 and -2. *Prog Lipid Res* 42, 377-404 (2003)

58. Spencer, A. G, J. W. Woods, T. Arakawa, I. I. Singer & W. L. Smith: Subcellular localization of prostaglandin endoperoxide H synthases-1 and -2 by immunoelectron microscopy. *J Biol Chem* 273, 9886-9893 (1998)

59. Parfenova, H, V. N. Parfenov, B. V. Shlopov, V. Levine, S. Falkos, M. Pourcyrous & C. W. Leffler: Dynamics of nuclear localization sites for COX-2 in vascular endothelial cells. *Am J Physiol Cell Physiol* 281, C166-C178 (2001)

60. Murakami, M. & I. Kudo: Recent advances in molecular biology and physiology of the prostaglandin E₂-biosynthetic pathway. *Prog Lipid Res* 43, 3-35 (2004)

61. Wu, K. K: Inducible cyclooxygenase and nitric oxide synthase. *Adv Pharmacol* 33, 179-207 (1995)

62. Vellucci, S.V. & R. F. Parrott: Expression of mRNAs for vasopressin, oxytocin and corticotropin releasing hormone in the hypothalamus, and of cyclooxygenases-1 and -2 in the cerebral vasculature, of endotoxin-challenged pigs. *Neuropeptides* 32, 439-446 (1998)

63. Stamme, C, D. S. Bundschun, T. Harting, U. Gebert, L. Wollin, R. Nusing, A. Wendel & S. Uhlig: Temporal sequence of pulmonary and systemic inflammatory responses to graded polymicrobial peritonitis in mice. *Infect Immun* 67, 5642-5650 (1999)

64. Shaftel, S. S, J. A. Olschowka, S. D. Hurley, A. H. Moore & M. K. O'Banion: COX-3: a splice variant of cyclooxygenase-1 in mouse neural tissue and cells. *Brain Res Mol Brain Res* 119, 213-215 (2003)

65. Dogan, M. D, H. Ataoglu & E. S. Akarsu: Effect of

selective cyclooxygenase enzyme inhibitors on lipopolysaccharide-induced dual thermoregulatory changes in rats. *Brain Res Bull* 57, 179-185 (2002)

66. Zhang, Y. H, J. Lu, J. K. Elmquist & C. B. Saper: Specific roles of cyclooxygenase-1 and cyclooxygenase-2 in lipopolysaccharide-induced fever and Fos expression in rat brain. *J Comp Neurol* 463, 3-12 (2003)

67. Li, S, Y. Wang, K. Matsumura, L.R. Ballou, S. G. Morham & C. M. Blatteis: The febrile response to lipopolysaccharide is blocked in cyclooxygenase-2^{-/-}, but not in cyclooxygenase-1^{-/-} mice. *Brain Res* 825, 86-94 (1999)

68. Liu, S. F, R. Newton, T. W. Evans & P. J. Barnes: Different regulation of cyclo-oxygenase-1 and cyclo-oxygenase-2 gene expression by lipopolysaccharide treatment *in vivo* in the rat. *Clin Sci* 90, 301-306 (1996)

69. Devaux, Y, C. Seguin, S. Grosjean, N. de Talance, V. Camaeti, A. Bulet, F. Zannad, C. Meistelman, P-M. Mertes & D. Longrois: Lipopolysaccharide-induced increase of prostaglandin E₂ is mediated by inducible nitric oxide synthase activation of the constitutive cyclooxygenase and induction of membrane-associated prostaglandin E synthase. *J Immunol* 167, 3962-3971 (2001)

70. Colville-Nash, P. R. & D. W. Gilroy: COX-2 and the cyclopentenone prostaglandins — a new chapter in the book of inflammation? *Prostaglandins Other Lipid Mediat* 62, 33-43 (2000)

71. Inoue, H, T. Tanabe & K. Umesono: Feedback control of cyclooxygenase-2 expression through PPARgamma. *J Biol Chem* 275, 28028-28032 (2000)

72. Mouihate, A, L. Boissé & Q. J. Pittman: Anovel antipyretic action of 15-deoxy-delta^{12,14}-prostaglandin J₂ in the rat brain. *J Neurosci* 24, 1312-1318 (2004)

73. Matsumura, K. & S. Kobayashi: Signaling the brain in inflammation: the role of endothelial cells. *Front. Biosci.* (2004, in press)

74. Katori, M. & M. Majima: Cyclooxygenase-2: its rich diversity of roles and possible application of its selective inhibitors. *Inflamm Res* 49, 367-392 (2000)

75. Cao, C, K. Matsumura, K. Yamagata & Y. Watanabe: Induction by lipopolysaccharide of cyclooxygenase-2 mRNA in rat brain; its possible role in the febrile response. *Brain Res* 697, 187-196 (1995)

76. Lacroix, S. & S. Rivest: Effect of acute systemic inflammatory response and cytokines on the transcription of the genes encoding cyclooxygenase enzymes (COX-1 and COX-2) in the rat brain. *J Neurochem* 70, 452-466 (1998)

77. Quan, N, M. Whiteside & M. Herkenham:

Metabolism of prostaglandin E₂ in fever

- Cyclooxygenase 2 mRNA expression in rat brain after peripheral injection of lipopolysaccharide. *Brain Res* 802, 189-197 (1998)
78. Cao, C, K. Matsumura, K. Yamagata and Y. Watanabe: Endothelial cells of the rat brain vasculature express cyclooxygenase-2 mRNA in response to systemic interleukin-1beta: a possible site of prostaglandin synthesis responsible for fever. *Brain Res* 733, 263-272 (1996)
79. Cao, C, K. Matsumura, K. Yamagata & Y. Watanabe: Cyclooxygenase-2 is induced in brain blood vessels during fever evoked by peripheral or central administration of tumor necrosis factor. *Brain Res Mol Brain Res* 56, 45-56 (1998)
80. Schiltz, J. C. & P. E. Sawchenko: Distinct brain vascular cells types manifest inducible cyclooxygenase expression as a function of the strength and nature of immune insults. *J Neurosci* 22, 5606-5618 (2002)
81. Schiltz, J. C. & P. E. Sawchenko: Signaling the brain in systemic inflammation: the role of perivascular cells. *Front Biosci* 8 (Suppl), s1321-s1329 (2003)
82. Romanovsky, A. A, A. I. Ivanov & E. K. Karman: Blood-borne, albumin-bound prostaglandin E₂ may be involved in fever. *Am J Physiol* 276: R1840-R1844 (1999)
83. Romanovsky, A. A, A. I. Ivanov & M. Székely: Neural route of pyrogen signaling to the brain. *Clin Infect Dis* 31 (Suppl 5), S162-S167 (2000)
84. Imai-Matsumura, K, K. Matsumura, A. Terao & Y. Watanabe: Attenuated fever in pregnant rats is associated with blunted syntheses of brain cyclooxygenase-2 and PGE₂. *Am J Physiol Regul Integr Comp Physiol* 283, R1346-R1353 (2002)
85. Ivanov, A. I. & A. A. Romanovsky: Near-term suppression of fever: inhibited synthesis or accelerated catabolism of prostaglandin E₂? *Am J Physiol Regul Integr Comp Physiol* 284, R860-R861 author reply R861-R865 (2003)
86. Jakobsson, P-J, S. Thoren, R. Morgenstern & B. Samuelsson: Identification of human prostaglandin E synthase: a microsomal, glutathione-dependent, inducible enzyme, constituting a potential novel drug target. *Proc Natl Acad Sci USA* 96, 7220-7225 (1999)
87. Tanioka, T, Y. Nakatani, N. Semmyo, M. Murakami & I. Kudo: Molecular identification of cytosolic prostaglandin E₂ synthase that is functionally coupled with cyclooxygenase-1 in immediate prostaglandin E₂ biosynthesis. *J Biol Chem* 275, 32775-32782 (2000)
88. Tanikawa, N, Y. Ohmiya, H. Ohkubo, K. Hashimoto, K. Kangawa, M. Kojima, S. Ito & K. Watanabe: Identification and characterization of a novel type of membrane-associated prostaglandin E synthase. *Biochem Biophys Res Commun* 291, 884-889 (2002)
89. Beuckmann, C. T, K. Fujimori, Y. Urade & O. Hayaishi: Identification of mu-class glutathione transferases M2-2 and M3-3 as cytosolic prostaglandin E synthases in the human brain. *Neurochem Res* 25, 733-738 (2000)
90. Murakami, M, K. Nakashima, D. Kamei, S. Masuda, Y. Ishikawa, T. Ishi, Y. Ohmiya, K. Watanabe & I. Kudo: Cellular prostaglandin E₂ production by membrane-bound prostaglandin E synthase-2 via both cyclooxygenases-1 and -2. *J Biol Chem* 278, 37937-37947 (2003)
91. Mancini, J. A, K. Blood, J. Guay, R. Gordon, D. Claveau, C-C. Chan & D. Riendeau: Cloning, expression and up-regulation of inducible rat prostaglandin E synthase during lipopolysaccharide-induced pyresis and adjuvant-induced arthritis. *J Biol Chem* 276, 4469-4475 (2001)
92. Yamagata, K, K. Matsumura, W. Inoue, T. Shiraki, K. Suzuki, S. Yashida, H. Sugiura, C. Cao, Y. Watanabe & S. Kobayashi: Coexpression of microsomal-type prostaglandin E synthase with cyclooxygenase-2 in brain endothelial cells of rats during endotoxin-induced fever. *J Neurosci* 21, 2669-2677 (2001)
93. Ek, M, D. Engblom, S. Saha, A. Blomqvist, P-J. Jakobsson & A. Ericsson-Dahlstrand: Pathway across the blood-brain barrier. *Nature* 410, 430-431 (2001)
94. Engblom, D, S. Saha, L. Engstrom, M. Westman, L. P. Audoly, P. J. Jakobsson & A. Blomqvist: Microsomal prostaglandin E synthase-1 is the central switch during immune-induced pyresis. *Nat Neurosci* 6, 1137-1138 (2003)
95. Uematsu, S, M. Matsumoto, K. Takeda & S. Akira: Lipopolysaccharide-dependent prostaglandin E₂ production is regulated by the glutathione-dependent prostaglandin E synthase gene induced by the Toll-like receptor 4/MyD88/NF-IL6 pathway. *J Immunol* 168, 5811-5816 (2002)
96. Trebino, C. E, J. L. Stock, C. P. Gibbons, B. M. Naiman, T. S. Wachtmann, J. P. Umland, K. Pandher, J. M. Lapointe, S. Saha, M. L. Roach, D. Carter, N. A. Thomas, B. A. Durtschi, J. D. McNeish, J. E. Hambor, P-J. Jakobsson, T. J. Carty, J. R. Perez & L. P. Audoly: Impaired inflammatory and pain responses in mice lacking an inducible prostaglandin E synthase. *Proc Natl Acad Sci USA* 100, 9044-9049 (2003)
97. Johnson, J. A, A. el Barbary, S. E. Kornguth, J. F. Brugge & F. L. Siegel: Glutathione S-transferase isoenzymes in rat brain neurons and glia. *J Neurosci* 13, 2013-2023 (1993)
98. Szelényi, Z, L. Barthó, M. Székely & A. A. Romanovsky: Cholecystokinin octapeptide (CCK-8) injected into a cerebral ventricle induces a fever-like thermoregulatory response mediated by type B CCK-

Metabolism of prostaglandin E₂ in fever

receptors in the rat. *Brain Res* 638, 69-77 (1994)

99. Romanovsky, A. A. & Y. K. Karman: Posthemorrhagic antipyresis: what stage of fever genesis is affected? *J Appl Physiol* 83, 359-365 (1997)

100. Sugimoto, N, C. T. Simons & A. A. Romanovsky: Vagotomy does not affect thermal responsiveness to intrabrain prostaglandin E₂ and cholecystokinin octapeptide. *Brain Res* 844, 157-163 (1999)

101. Hamberg, M. & B. Samuelsson: On the metabolism of prostaglandins E₁ and E₂ in man. *J Biol Chem* 246, 6713-6721 (1971)

102. Samuelsson, B: Prostaglandins and related factors: synthesis of tritium-labeled prostaglandin E₁ and studies on its distribution and excretion in the rat. *J Biol Chem* 239, 4091-4096 (1964)

103. Piper, P. J, J. R. Vane & J. H. Wyllie: Inactivation of prostaglandins by the lungs. *Nature* 225, 600-604 (1970)

104. Nakano, J, A. V. Prancar & S. E. Moore: Metabolism of prostaglandin E₁ in the cerebral cortex and cerebellum of the dog and rat. *Brain Res* 39, 545-548 (1972)

105. DiBenedetto, F. E. & L. Z. Bito: Transport of prostaglandins and other eicosanoids by the choroid plexus: its characterization and physiological significance. *J Neurochem* 46, 1725-1731 (1986)

106. Bito, L. Z, H. Davson & E. V. Salvador: Inhibition of *in vitro* concentrative prostaglandin accumulation by prostaglandins, prostaglandin analogues and by some inhibitors of organic anion transport. *J Physiol* 256, 257-271 (1976)

107. Bito, L. Z, M. Wallenstein & R. Barody: The role of transport processes in the distribution and disposition of prostaglandins. *Adv Prostaglandin Tromboxane Res* 1, 297-303 (1976)

108. Schuster, V. L: Prostaglandin transport. *Prostaglandins Other Lipid Mediators* 68-69, 633-647 (2002)

109. Schuster, V. L: Molecular mechanisms of prostaglandin transport. *Annu Rev Physiol* 60, 221-242 (1998)

110. Bito, L. Z, R. A. Baroody & M. E. Reitz: Dependence of pulmonary prostaglandin metabolism on carrier-mediated transport processes. *Am J Physiol* 232, E382-E387 (1977)

111. Kanai, N, R. Lu, J. A. Satriano, Y. Bao, A. W. Wolkoff & V. L. Schuster: Identification and characterization of a prostaglandin transporter. *Science* 268, 866-869 (1995)

112. Nishio, T, H. Adachi, R. Nakagomi, T. Tokui, E. Sato,

M. Tanemoto, K. Fujiwara, M. Okabe, T. Onogawa, T. Suzuki, D. Nakai, K. Shiiba, M. Suzuki, H. Ohtani, Y. Kondo, M. Unno, S. Ito, K. Iinuma, K. Nunoki, S. Matsuno & T. Abe: Molecular identification of a rat novel organic anion transporter moat1, which transports prostaglandin D₂, leukotriene C₄, and taurocholate. *Biochem Biophys Res Commun* 275, 831-838 (2000)

113. Kimura, H, M. Takeda, S. Narikawa, A. Enomoto, K. Ichida & H. Endou: Human organic anion transporters and human organic cation transporters mediate renal transport of prostaglandins. *J Pharmacol Exp Ther* 301, 293-298 (2002)

114. Endo, S, T. Nomura, B. S. Chan, R. Lu, M. L. Pucci, Y. Bao & V. L. Schuster: Expression of PGT in MDCK cell monolayers: polarized apical localization and induction of active PG transport. *Am J Physiol Renal Physiol* 282, F618-F622 (2002)

115. Bito, L. Z: The effects of experimental uveitis on anterior uveal prostaglandin transport and aqueous humoral composition. *Invest Ophthalmol* 13, 959-966 (1974)

116. Topper, J. N, J. Cai, G. Stavrakis, K. R. Anderson, E. A. Wolf, B. A. Sampson, F. J. Schoen, D. Falb & M. A. Gimbrone Jr: Human prostaglandin transporter gene (hPGT) is regulated by fluid mechanical stimuli in cultured endothelial cells and expressed in vascular endothelium *in vivo*. *Circulation* 98, 2396-2403 (1998)

117. Ivanov, A. I, A. C. Scheck & A. A. Romanovsky: Expression of genes controlling transport and catabolism of prostaglandin E₂ in lipopolysaccharide fever. *Am J Physiol Regul Integr Comp Physiol* 284, R698-R706 (2003)

118. Matsumura, K, R. Okamura, W. Inoue, K. Yamagata & S. Kobayashi: Induction of prostaglandin transporter (pgt) in brain endothelial cells and arachnoidal membrane of rat after systemic injection of pyrogen lipopolysaccharide (Abstract). Program #280.4. 2003 Abstract Viewer/Itinerary Planner. Washington, DC: Society for Neuroscience (2003)

119. Anggard, E: The biological activity of three metabolites of prostaglandin E₁. *Acta Physiol Scand* 66, 509-510 (1966)

120. Forrest, G. L. & B. Gonzales: Carbonyl reductase. *Chem Biol Interact* 129, 21-40 (2000)

121. Ensor, C. M. & H-H. Tai: Hydroxyprostaglandin dehydrogenase. *J Lipid Mediat Cell Signal* 12, 313-319, (1995)

122. Terada, T, Y. Sugihara, K. Nakamura, R. Sato, S. Sakuma, Y. Fujimoto, T. Fujita, N. Inazu & M. Maeda: Characterization of multiple Chinese hamster carbonyl reductases. *Chem Biol Interact* 130-132, 847-861 (2001)

123. Taiwo, Y. O. & J. D. Levine: Indomethacin blocks central nociceptive effects of PGF_{2α}. *Brain Res* 373, 81-

Metabolism of prostaglandin E₂ in fever

84 (1986)

124. Wermuth, B, G. Mader-Heinemann & E. Ernst: Cloning and expression of carbonyl reductase from rat testis. *Eur J Biochem* 228, 473-479 (1995)

125. Coggins, K. G, A. Latour, M. S. Nguyen, L. Audoly, T. M. Coffman & B. H. Koller: Metabolism of PGE₂ by prostaglandin dehydrogenase for remodeling the ductus arteriosus. *Nature Med* 8, 91-92 (2002)

126. Gregory, M. S, L. A. Duffner, E. L. Hahn, H-H. Tai, D. E. Faunce & E. J. Kovacs: Differential production of prostaglandin E₂ in male and female mice subjected to thermal injury contributes to the gender difference in immune function: possible role for 15-hydroxyprostaglandin dehydrogenase. *Cell Immunol* 205, 94-102 (2000)

127. Pomini, F, A. Caruso & J. R. G. Challis: Interleukin-10 modifies the effects of interleukin-1beta and tumor necrosis factor-alpha on the activity and expression of prostaglandin H synthase-2 and the NAD⁺-dependent 15-hydroxyprostaglandin dehydrogenase in cultured term human villous trophoblast and chorion trophoblast cells. *J Clin Endocrinol Metab* 84, 4645-4651 (1999)

128. Mitchell, M. D, V. Goodwin, S. Mesnage & J. A. Keelan: Cytokine-induced coordinated expression of prostaglandin biosynthesis and metabolism: 15-hydroxyprostaglandin dehydrogenase. *Prostaglandins Leukot Essent Fatty Acids* 62, 1-5 (2000)

129. Nakano, J. & A. V. Prancan: Metabolic degradation of prostaglandin E₁ in the lung and kidney of rats in endotoxin shock. *Proc Soc Exp Biol Med* 144, 506-508 (1973)

130. Blackwell, G. J, R. J. Flower & A. G. Herman: Effect of endotoxin on 15-hydroxyprostaglandin dehydrogenase in the rabbit jejunum and lung. *Arc Int Pharmacodyn Ther* 220, 325-326 (1976)

131. Hahn, E. L, K. D. Clancy, H-H. Tai, J. D. Ricken, L. K. He & R. L. Gamelli: Prostaglandin E₂ alterations during sepsis are partially mediated by endotoxin-induced inhibition of prostaglandin 15-hydroxydehydrogenase. *J Trauma* 44, 777-781 (1998)

132. Blackwell, G. J, R. J. Flower & J. R. Vane: Rapid reduction of prostaglandin 15-hydroxydehydrogenase activity in rat tissues after treatment with protein synthesis inhibitors. *Br J Pharmacol* 55, 233-238 (1975)

133. Davidson, J, H. T. Abul, A. S. Milton & D. Rotondo: Cytokines and cytokine inducers stimulate prostaglandin E₂ entry into the brain. *Pflügers Arch* 442, 526-533 (2001)

134. Lu, R. & V. L. Schuster: Molecular cloning of the gene for the human prostaglandin transporter hPGT: gene organization, promoter activity, and chromosomal localization. *Biochem Biophys Res Commun* 246, 805-

812 (1998)

135. Matsuo, M, C. M. Ensor & H-H. Tai: Characterization of the genomic structure and promoter of the mouse NAD⁺-dependent 15-hydroxyprostaglandin dehydrogenase gene. *Biochem Biophys Res Commun* 235, 582-586 (1997)

136. Denson, L. A, R. K. Menon, A. Shafl, H. S. Bajwa, C. R. Williams & S. J. Karpen: TNF-alpha downregulates murine hepatic growth hormone receptor expression by inhibiting Sp1 and Sp3 binding. *J Clin Invest* 107, 1451-1458 (2001)

137. Ye, X. & S. F. Liu: Lipopolysaccharide regulates constitutive and inducible transcription factor activities differentially *in vivo* in the rat. *Biochem Biophys Res Commun* 288, 927-932 (2001)

138. Dogan, M. D, V. A. Kulchitsky, S. Patel, E. Pétervári, M. Székely & A. A. Romanovsky: Bilateral splanchnicotomy does not affect lipopolysaccharide-induced fever in rats. *Brain Res* 993, 227-229 (2003)

139. The Commission for Thermal Physiology of the International Union of Physiological Sciences (IUPS Thermal Commission): Glossary of terms for thermal physiology: third edition. *Jpn J Physiol* 51, i-xxxvi (2001)

140. Romanovsky, A. A: Thermoregulatory manifestations of systemic inflammation: lessons from vagotomy. *Auton Neurosci* 85, 39-48 (2000)

141. Simons, C. T, V. A. Kulchitsky, N. Sugimoto, L. D. Homer, M. Székely & A. A. Romanovsky: Signaling the brain in systemic inflammation: which vagal branch is involved in fever genesis? *Am J Physiol* 275, R63-R68 (1998)

142. Ek, M, M. Kurosawa, T. Lundeberg, M. Heilig & A. Ericsson: Activation of vagal afferents after intravenous injection of interleukin-1beta: role of endogenous prostaglandins. *J Neurosci* 18, 9471-9479 (1998)

143. Ushikubi, F, E. Segi, Y. Sugimoto, T. Murata, T. Matsuoka, T. Kobayashi, H. Hizaki, K. Tuboi, M. Katsuyama, A. Ichikawa, T. Tanaka, N. Yoshida & S. Narumiya: Impaired febrile response in mice lacking the prostaglandin E receptor subtype EP3. *Nature* 395, 281-284 (1998)

144. Oka, T: Prostaglandin E₂ as a mediator of fever: prostaglandin receptors. *Front Biosci* (2004, in press)

145. Nijijima, A: The afferent discharges from sensors for interleukin-1beta in the hepatoportal system in the anesthetized rat. *J Auton Nerv Syst* 61, 287-291 (1996)

146. Dascombe, M. J. & A. S. Milton: Study on the possible entry of bacterial endotoxin and prostaglandin E₂ into the central nervous system from the blood. *Br J Pharmacol* 66, 565-572 (1979)

147. Skarnes, R. C, S. K. Brown, S. S. Hull & J. A.

Metabolism of prostaglandin E₂ in fever

McCracken: Role of prostaglandin E in biphasic fever response to endotoxin. *J Exp Med* 154, 1212-1224 (1981)

148. Morimoto, A, N. Murakami, T. Nakamori, & T. Watanabe: Multiple control of fever production in the central nervous system in rabbits. *J Physiol* 397, 269-280 (1988)

149. Saper, C. B. & C. D. Breder: The neurologic basis of fever. *N Engl J Med* 330, 1880-1886 (1994)

150. Morimoto, A, K. Morimoto, T. Watanabe, Y. Sakata & N. Murakami: Does an increase in prostaglandin E₂ in the blood circulation contribute to a febrile response in rabbits? *Brain Res Bull* 29, 189-192 (1992)

151. Botting, R: Antipyretic therapy. *Front Biosci* 9, 956-966 (2004)

152. Flower, R. J. & J. R. Vane: Inhibition of prostaglandin synthetase in brain explains the anti-pyretic activity of paracetamol (4-acetamidophenol). *Nature* 240, 410-411 (1972)

153. Romanovsky, A. A, C. T. Simons, M. Székely & V. A. Kulchitsky: The vagus nerve in the thermoregulatory response to systemic inflammation. *Am J Physiol* 273, R407-R413 (1997)

154. Ivanov, A. I, S. Patel, V. A. Kulchitsky & A. A. Romanovsky: Platelet-activating factor: a previously unrecognized mediator of fever. *J Physiol* 553, 221-228 (2003)

155. Romanovsky, A. A, A. I. Ivanov & Y. P. Shimansky: Selected contribution: ambient temperature for experiments in rats: a new method for determining the zone of thermal neutrality. *J Appl Physiol* 92, 2667-2679 (2002)

156. Ueno, R, S. Narumiya, T. Ogorochi, T. Nakayama, Y. Ishikawa & O. Hayaishi: Role of prostaglandin D₂ in the hypothermia of rats caused by bacterial lipopolysaccharide. *Proc Natl Acad Sci USA* 79, 6093-6097 (1982)

157. Brus, R, T. Krzeminski, Z. Juraszczyk, A. Kurcok, W. Felinska & W. Kozik: Central effects of leukotriene C₄ and D₄ in rats and mice. *Biomed Biochim Acta* 45, 1153-1158 (1986)

158. Romanovsky, A. A. & C. M. Blatteis: Biphasic fever: what triggers the second temperature rise? *Am J Physiol* 269, R280-R286 (1995)

159. Székely, M, M. Balaskó, V. A. Kulchitsky, C. T. Simons, A. I. Ivanov & A. A. Romanovsky: Multiple neural mechanisms of fever. *Auton Neurosci* 85, 78-82 (2000)

Abbreviations: In addition to the commonly accepted (*e.g.*, mRNA), the following abbreviations are used in this paper (all introduced at first mentioning). AA, arachidonic acid, BBB, blood-brain barrier, c, cytosolic, as in cPLA₂ or cPGES, CR, carbonyl reductase, COX, cyclooxygenase(s), GST, glutathione-S-transferase(s), IL, interleukin, LPS, lipopolysaccharide, m, microsomal, as in mPGES, MOAT,

multispecific organic anion transporter, PAF, platelet-activating factor, PG, prostaglandin(s), 15d-PGJ₂, 15-deoxy-delta^{12,14}-PGJ₂, 15-PGDH, 15-hydroxy-PG dehydrogenase, PGES, PGE synthase(s), PGT, PG transporter, PL, phospholipase(s), s, secretory, as in sPLA₂, TNF, tumor necrosis factor

Key Words: Body temperature, Thermoregulation, Fever, Febrile phases, Lipopolysaccharide, Prostaglandins, PGE₂, Phospholipases, PLA₂, Cyclooxygenases, COX-1, COX-2, Terminal synthases, PGES, Prostaglandin transporter, PGT, MOAT, Prostaglandin dehydrogenases, 15PGDH, Carbonyl reductase, CR, Expression, Transcriptional regulation, Review

Send correspondence to: Andrej A. Romanovsky, M.D., Ph.D., Director, Systemic Inflammation Laboratory, Trauma Research, St. Joseph's Hospital and Medical Center, 350 West Thomas Road, Phoenix, Arizona 85013, USA, Tel: 602-406-5059, Fax: 602-406-4113, E-mail: aromano@chw.edu